Relationship between pre-treatment serum SCC (squamous cell carcinoma) antigen, Cyfra 21-1 levels, and survival in squamous cell carcinoma of the uterine cervix.

PURPOSE To determine the relationship between pretreatment serum squamous cell carcinoma (SCC) antigen and Cyfra 21-1 levels, and survival in patients with invasive squamous cell carcinoma of the cervix. MATERIALS AND METHODS One hundred and one cervical squamous cell carcinoma patients were included. Pre-treatment levels of serum SCC antigen and Cyfra 21-1 were measured, with a 5 year minimum follow up. Thirty two recurrent disease (RD) patients were compared to 99 non-recurrent disease (NRD) patients with respect to tumor markers, FIGO stage, lesion size, lymph node status, and parametrial involvement. RESULTS Pre-treatment serum SCC antigen and Cyfra 21-1 levels were significantly higher in the RD group (p<0.001). Combined serum SCC antigen and Cyfra 21-1 levels showed higher sensitivity for prediction of recurrence (90.6%). Pre-treatment SCC antigen and Cyfra 21-1 levels showed correlation with high FIGO stage, large lesion size, lymph node status, and parametrial involvement (p<0.001). Normal pre-treatment levels of SCC antigen and Cyfra 21-1 showed a 5-year survival rate of 93% and 90% respectively, while elevated levels showed significantly decreased survival rate of 63% and 59%, respectively (p<0.001). Odd ratio for cumulative survival rates were 6.87 for SCC antigen, and 5.07 for Cyfra 21-1 (p<0.001). CONCLUSION Initial pre-treatment levels of serum SCC antigen and Cyfra 21-1 are closely related to FIGO stage, lesion size, lymph node and parametrial involvement in patients with squamous cell carcinoma of the cervix. Also, these markers may be of help to predicting recurrent disease and survival rates.

[1]  A. Gadducci,et al.  Serum tumor markers in the management of ovarian, endometrial and cervical cancer. , 2004, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[2]  C. Lautenschläger,et al.  SCC antigen in the serum as an independent prognostic factor in operable squamous cell carcinoma of the cervix. , 2002, European journal of cancer.

[3]  N. Sakuragi,et al.  Preoperative serum SCC, CA125, and CA19‐9 levels and lymph node status in squamous cell carcinoma of the uterine cervix , 2002, Acta obstetricia et gynecologica Scandinavica.

[4]  M. Chun,et al.  Clinical value of pretreatment serum cyfra 21-1 and SCC Ag levels in cervical cancer patients. , 2001 .

[5]  M. J. van de Vijver,et al.  Can initial serum cyfra 21-1, SCC antigen, and TPA levels in squamous cell cervical cancer predict lymph node metastases or prognosis? , 2000, Gynecologic oncology.

[6]  M. Yen,et al.  Application of tumor markers CEA, TPA, and SCC-Ag in patients with low-risk FIGO stage IB and IIA squamous cell carcinoma of the uterine cervix. , 2000, Gynecologic oncology.

[7]  M. Pichon,et al.  Cancer of the uterine cervix: sensitivity and specificity of serum Cyfra 21.1 determinations. , 1998, European journal of gynaecological oncology.

[8]  G. Kenter,et al.  Value of Cyfra 21-1, TPA, and SCC-Ag in predicting extracervical disease and prognosis in cervical cancer. , 1997, Anticancer research.

[9]  P. Kenemans,et al.  Cyfra 21-1 in monitoring cervical cancer: a comparison with tissue polypeptide antigen and squamous cell carcinoma antigen. , 1997, Anticancer research.

[10]  C. Kao,et al.  Study of a new tumor marker, CYFRA 21-1, in squamous cell carcinoma of the cervix, and comparison with squamous cell carcinoma antigen. , 1996, Neoplasma.

[11]  K. Nasu,et al.  Serum levels of cytokeratin 19 fragments in cervical cancer. , 1996, Gynecologic and obstetric investigation.

[12]  H. Hollema,et al.  Pretreatment serum squamous cell carcinoma antigen: a newly identified prognostic factor in early-stage cervical carcinoma. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  G. Kenter,et al.  Clinical value of pretreatment serum Cyfra 21–1, tissue polypeptide antigen, and squamous cell carcinoma antigen levels in patients with cervical cancer , 1995, Cancer.

[14]  C. Kainz,et al.  Cytokeratin subunit 19 measured by CYFRA 21-1 assay in follow-up of cervical cancer. , 1995, Gynecologic oncology.

[15]  A. Hart,et al.  Prognostic significance of serum fragments of cytokeratin 19 measured by Cyfra 21-1 in cervical cancer. , 1994, Gynecologic oncology.

[16]  P. Stieber,et al.  Cytokeratin 19 fragments: a new marker for non-small-cell lung cancer. , 1993, Clinical biochemistry.

[17]  H. Hollema,et al.  Cancer of the uterine cervix: sensitivity and specificity of serum squamous cell carcinoma antigen determinations. , 1990, Gynecologic oncology.

[18]  T. Montag.  Tumor markers in gynecologic oncology. , 1990, Obstetrical & gynecological survey.

[19]  H. Shingleton,et al.  Monitoring the course of cervical carcinoma with the squamous cell carcinoma serum radioimmunoassay , 1989, Obstetrics and gynecology.

[20]  R. Moll,et al.  Cytokeratins of normal epithelia and some neoplasms of the female genital tract. , 1983, Laboratory investigation; a journal of technical methods and pathology.

[21]  H. Kato,et al.  Radioimmunoassay for tumor antigen of human cervical squamous cell carcinoma , 1977, Cancer.